BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 3, 2026
Home » Authors » Anette Breindl

Anette Breindl

Articles

ARTICLES

Bench Press: BioWorld looks at translational medicine

Feb. 6, 2017
By Anette Breindl
The response to stress is controlled by the hypothalamic-pituitary-adrenal (HPA) axis, and dysfunction of the HPA axis induced by chronic stress puts individuals at risk of a variety of psychiatric as well as physiological conditions.
Read More

Clotting, hypertension, inflammation linked

Feb. 3, 2017
By Anette Breindl
Factor XI, a coagulation factor that is part of the intrinsic blood clotting pathway, is part of a newly discovered circuit that links coagulation, inflammation and hypertension. Researchers described the circuit, which breaks ground scientifically as well as offering potential therapeutic strategies to treat often-co-morbid diseases, in the Feb. 1, 2017, issue of Science Translational Medicine.
Read More

Exploiting IDH mutations could be therapeutic approach

Feb. 2, 2017
By Anette Breindl
In a situation analogous to BRCA-mutated tumors, isocitrate dehydrogenase (IDH) mutations led to defects in DNA damage repair and rendered tumor cells vulnerable to poly ADP-ribose polymerase (PARP) inhibitors, researchers have reported.
Read More

Bench Press: BioWorld looks at translational medicine

Jan. 30, 2017
By Anette Breindl
The cell surface protein CD99 is expressed on cancer stem cells in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS), and it could serve as both a marker and a therapeutic target in those disorders.
Read More

Chimeras give insights into embryology and transplantation

Jan. 30, 2017
By Anette Breindl
Basic developmental biology and organ transplantation both got a boost this week, with two groups reporting progress in generating chimeras, and generating medically useful cell types using those chimeras.
Read More

Disconnect continues between Alzheimer’s science and clinic

Jan. 27, 2017
By Anette Breindl
In 2012, BioWorld named the disconnect between science and clinical trials in Alzheimer’s disease (AD) as one of the top 10 stories of the year. (See BioWorld Today, Dec. 27, 2012.)
Read More

Bench Press: BioWorld looks at translational medicine

Jan. 23, 2017
By Anette Breindl
Researchers at Stanford University have developed a way to image chimeric antigen receptor (CAR) T cells in patients by adding a positron emission tomography (PET) reporter gene to glioma-targeting cells. The same team had previously shown that in a single patient, such CAR T cells could be visualized after an autologous transplant, but due to constraints of the study protocol, it was not possible to take a baseline reading. In the current phase I study, the researchers treated seven patients with reporter gene-containing CAR T cells and showed that they could track the infused cells, though the study was not powered to relate cell uptake into tumors to clinical outcome.
Read More

In some tumors, heterogeneity only in passenger mutations

Jan. 20, 2017
By Anette Breindl
Tumor heterogeneity, the diverging evolution of both different subparts of primary tumors and of metastases compared to the primary tumor, is often named among the challenges for targeted treatment.
Read More

Dual-action, dual-indication decoy fights tumors, viruses

Jan. 17, 2017
By Anette Breindl
Inhibiting the Axl kinase could have applications in both antitumor and antiviral therapy, separate papers published over the past few weeks have reported. In the Jan. 10, 2017, issue of Cell Reports, a team from the French INSERM Institute showed that Axl receptor activity both enabled Zika virus entry into cells and modulated innate immune responses.
Read More

Bench Press: BioWorld looks at translational medicine

Jan. 17, 2017
By Anette Breindl
Tumor cells could induce autophagy in neighboring cells of the microenvironment and use resulting macromolecules for their own nutritional gains, and early stage tumors were dependent on microenvironmental autophagy for their growth.
Read More
View All Articles by Anette Breindl

Popular Stories

  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Neurons

    AA meeting of minds as PTC, Novartis push votoplam in HD

    BioWorld
    What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
  • Nerves within a melanoma tumor

    Innervation can slow, as well as speed, tumor growth, study finds

    BioWorld
    Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing